ERBB2 and breast cancer: Twelve phase III RCTs assessed therapies targeting HER2+ metastatic BC in the first-line setting (Slamon et al. [1]; Swain et al. [2]; Andersson et al. [12]; Baselga et al. [13]; Baselga et al. [14]; Guan et al. [15]; Inoue et al. [16]; Johnston et al. [17]; Kaufman et al. [18]; Robert et al. [19]; Schwartzberg et al. [20]; Swain et al. [21]; Valero et al. [22]; Gelmon et al. [31]; Hurwitz et al. [32]).